Ahmad, Jumana
Ellis, Claire http://orcid.org/0000-0002-1064-2395
Leech, Robert
Voytek, Bradley
Garces, Pilar
Jones, Emily
Buitelaar, Jan
Loth, Eva http://orcid.org/0000-0001-9458-9167
dos Santos, Francisco Páscoa
Amil, Adrián F.
Verschure, Paul F. M. J.
Murphy, Declan http://orcid.org/0000-0002-6664-7451
McAlonan, Grainne
Funding for this research was provided by:
Autism Speaks
Autistica
Article History
Received: 9 August 2022
Revised: 22 August 2022
Accepted: 6 October 2022
First Online: 8 November 2022
Competing interests
: JB has been for the past 3 years a consultant to/member of the advisory board of/and/or speaker for Janssen Cilag BV, Takeda/Shire, Roche, Medicine, Angelini and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. DM has received consultancy fees from F. Hoffmann-La Roche and Servier. GM has received consultancy fees from Greenwich Biosciences. GM and DM are supported by the Sackler Institute for Translational Neurodevelopment, the MRC Centre for Neurodevelopmental Disorders, and the NIHR-Maudsley Biomedical Research Center. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. PG is an employee of F. Hoffmann-La Roche Ltd. The remaining authors declare no competing interests.